Jefferies Gives Astrazeneca PLC Common Stock (NYSE:AZN) a Higher Rating. Raises its Hold Rating

March 19, 2018 - By Clifton Ray

  Jefferies Gives Astrazeneca PLC Common Stock (NYSE:AZN) a Higher Rating. Raises its Hold Rating

Astrazeneca PLC Common Stock (NYSE:AZN) Stock Upgrade

In an analyst note shared with investors and clients on 19 March, equity research analysts at the Jefferies equities division raised shares of Astrazeneca PLC Common Stock (NYSE:AZN) stock from a Hold to a respectable Buy rating.

AstraZeneca PLC (NYSE:AZN) Ratings Coverage

Among 26 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 17 have Buy rating, 0 Sell and 9 Hold. Therefore 65% are positive. AstraZeneca plc (ADR) has $50 highest and $32 lowest target. $40.14’s average target is 15.94% above currents $34.62 stock price. AstraZeneca plc (ADR) had 45 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was upgraded by JP Morgan on Friday, December 29 to “Overweight”. The firm has “Hold” rating given on Monday, April 10 by Jefferies. The stock of AstraZeneca PLC (NYSE:AZN) earned “Buy” rating by Jefferies on Monday, March 19. The rating was upgraded by HSBC on Wednesday, September 2 to “Buy”. The rating was maintained by BMO Capital Markets on Thursday, September 14 with “Buy”. Cantor Fitzgerald initiated the shares of AZN in report on Friday, February 26 with “Buy” rating. Liberum Capital downgraded AstraZeneca PLC (NYSE:AZN) on Thursday, September 14 to “Hold” rating. Leerink Swann maintained AstraZeneca PLC (NYSE:AZN) rating on Monday, May 2. Leerink Swann has “Market Perform” rating and $34 target. The rating was upgraded by Oddo & Cie on Tuesday, January 26 to “Top Pick”. Cowen & Co maintained the stock with “Hold” rating in Thursday, July 27 report.

The stock increased 0.09% or $0.03 during the last trading session, reaching $34.62. About 2.17M shares traded. AstraZeneca PLC (NYSE:AZN) has risen 19.45% since March 19, 2017 and is uptrending. It has outperformed by 2.75% the S&P500.

Analysts await AstraZeneca PLC (NYSE:AZN) to report earnings on April, 26. They expect $0.44 earnings per share, down 55.56 % or $0.55 from last year’s $0.99 per share. AZN’s profit will be $1.09B for 19.67 P/E if the $0.44 EPS becomes a reality. After $1.30 actual earnings per share reported by AstraZeneca PLC for the previous quarter, Wall Street now forecasts -66.15 % negative EPS growth.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of $86.00 billion. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 29.22 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.